Adverum aspires to transform the standard of care, preserve long-term vision, and create a profound societal impact around the globe, by advancing gene therapies for highly prevalent …

Adverum Biotechnologies is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness.

Adverum’s novel AAV vector technology has been engineered to serve a similar purpose. Our lead candidate, Ixo-vec, uses our proprietary AAV.7m8 vector capsid to carry a coding sequence for the anti-VEGF protein aflibercept in order to transduce its production in retina cells.

REDWOOD CITY, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for...

Feb 8, 2024 · Adverum Biotechnologies Inc announced preliminary safety and efficacy data from the ongoing LUNA Phase 2 trial in patients with wet age-related macular degeneration (AMD).

Nov 18, 2024 · Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with …

Nov 25, 2024 · Adverum President and CEO Laurent Fischer, MD, noted that both OPTIC’s Ixo-vec dosage of 2E11 results and the phase 2 LUNA efficacy data at 52 weeks show maintenance of visual and anatomic endpoints “with over 80% reduction in injection burden and greater than 50% injection freedom.”

Mar 4, 2025 · Adverum Biotechnologies has initiated its ARTEMIS phase 3 study to evaluate the efficacy and safety of ixoberogene soroparvovec (Ixo-vec) for patients with neovascular (wet) age-related macular degeneration (AMD).

Adverum is advancing the clinical development of its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with wet age-related macular degeneration.

Mar 3, 2025 · Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age...